---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-009487"
form_type: "8-K"
ticker: "FNCHQ"
cik: "0001733257"
company_name: "Finch Therapeutics Group, Inc."
filed_at: "2023-03-23T23:59:59+00:00"
generated_at: "2026-06-17T18:49:43.963069+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Finch Therapeutics Q4 net loss $27M, cash $71M; patent litigation progress, PRISM4 discontinued

## Summary
- Net loss Q4 $27.0M vs $19.1M in Q4 2021; FY2022 net loss $114.6M vs $58.2M in prior year.
- Cash and equivalents $71.0M at Dec 31, 2022; estimated $43.3M at Feb 28, 2023; cash runway extended into 2025.
- Discontinued PRISM4 Phase 3 trial for CP101 in recurrent C. difficile; database locked, no treatment-related SAEs.
- Court adopted Finch's claim constructions for 7/8 terms in patent case vs Ferring/Rebiotix; jury trial set May 2024.
- Repaid $16.2M debt to Hercules, subleased Hood Park facility, and launched Strain Bank for licensing.

## SEC filing metadata
- accession: 0000950170-23-009487
- form_type: 8-K
- ticker: FNCHQ
- cik: 0001733257
- company_name: Finch Therapeutics Group, Inc.
- filed_at: 2023-03-23T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1733257/000095017023009487/0000950170-23-009487-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1733257/000095017023009487/fnch-20230323.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-009487
- JSON: https://secwatch.observer/filing/0000950170-23-009487.json
- Plain text: https://secwatch.observer/filing/0000950170-23-009487.txt

## Key facts
- Earnings Releases
  Finch Therapeutics Group, Inc. reported the fourth quarter of 2022 results: net income $27.0 million.
  - Period: the fourth quarter of 2022
  - Net income: $27.0 million
  - Result: reported results
  source text: Finch reported a net loss of $27.0 million for the fourth quarter of 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1733257/000095017023009487/0000950170-23-009487-index.htm
- Earnings Releases
  Finch Therapeutics Group, Inc. reported the full year of 2022 results: net income $114.6 million.
  - Period: the full year of 2022
  - Net income: $114.6 million
  - Result: reported results
  source text: Finch reported a net loss of $114.6 million for the full year of 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1733257/000095017023009487/0000950170-23-009487-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.